Propecia Generic For Male Pattern Baldness

The drug propecia generic was originally intended for treating prostate enlargement or benign prostatic hyperplasia. When its branded name Proscar was released in the market, it was noticed that men who were suffering from androgenic alopecia were also being treated by the drug.  It was then that the manufacturer took notice and created some clinical studies and found out that Proscar, which came at 5mg, which at lowered dosage, particularly 1mg, could help fight androgenic alopecia.  Several years later, the brand Propecia, an offshoot of the drug Proscar was approved by the Food and Drug Administration as a treatment for androgenic alopecia.

Who is propecia generic intended for?

Propecia generic is meant for men suffering from male pattern baldness and want to stop the progression of their hair loss.  Signs of male pattern baldness would be the thinning of hair on the front, the receding of hairline on the temples, and the formation of a bald spot on the crown.  In due time, this type of baldness will let you end up bald from top to front with a rim of hair at the sides and back.  propecia generic is effective against this type of hair loss because it is able to treat it at the root of the cause – the formation of the hormone dihydrotestosterone (DHT).  Basically, this hair loss treatment prevents your hair loss from getting any worse.  If your hair loss is due to androgenic alopecia, then this is the medication for you.  Consult your doctor to know what type of hair loss you are having. Read more…

Getting drug addiction treatment on track

Implants may trump liquid and pills

Methadone has helped countless people hooked on heroin and prescription pain relievers wean themselves off for over 40 years. A methadone alternative may soon outshine the well-known withdrawal aid in some important ways.

Buprenorphine hydrochloride, a semi-synthetic opioid compound used for pain control and detoxification, has been available in pill form for two years. But its downside includes diverting the tablets for sale on the streets and crushing and liquefying them into an injectable – and therefore more potent -- form.

A recent study published in the Journal of the American Medical Association (http://jama.ama-assn.org/cgi/content/short/304/14/1576) shows promise for a buprenorphine implant, called Probuphine by its California makers, Titan Pharmaceuticals.

One hundred and sixty-three opioid-dependent adults (18-65 years of age) received either four 3-cm long (a centimeter shy of the width of a ping-pong ball), ethylene vinyl acetate and buprenorphine implants, or 4 dummy rods for 6 months. The 108 participants with the real deal received 80 mg per implant. All the subjects were given drug counselling, and urine samples were taken to detect illicit drug use.

If anyone felt the slow-release dose from the implants did not combat their cravings sufficiently, they could request sublingual tablets. Over the first 16 weeks, about 60% of the buprenorphine group requested extra doses, while over 90% of the placebo-implanted group did. Urine samples tested negative for illicit opioids more often in the buprenorphine implant group than the placebo group (approximately 40% vs 28%) over the same timeframe. And more of the buprenorphine group opted to stay in the study for the full 24 weeks (66% vs 31%).

Cravings and other withdrawal symptoms were generally reduced in the treatment group, although there were minor adverse reactions reported, i.e. discomfort at the implant site, in both groups.

Considering that Canada ranks almost as high as Germany and the U.S. for prescription opioid use, a six-month implant may be well worth the trouble – as long as it doesn’t dissuade regular visits to the clinic for counselling.
Milena Katz